Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder.
Mult Scler Relat Disord
; 85: 105551, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38564996
ABSTRACT
BACKGROUND:
Sphingolipids are signaling molecules and structural components of the axolemma and myelin sheath. Plasma sphingolipid levels may reflect disease status of neuromyelitis optica spectrum disorder (NMOSD). We aimed to examine plasma sphingolipids as disease severity biomarkers for NMOSD and compare their characteristics with those of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP).METHODS:
We measured plasma sphingolipids, sNfL, and sGFAP levels in NMOSD cases with anti-aquaporin-4-antibody. An unbiased approach, partial least square discriminant analysis (PLS-DA), was utilized to determine whether sphingolipid profiles differ according to the disease state of NMOSD (presence, moderate-to-severe disability [Expanded Disease Severity Scale, (EDSS) > 3.0], and relapses).RESULTS:
We investigated 81 patients and 10 controls. PLS-DA models utilizing sphingolipids successfully differentiated patients with EDSS > 3.0, but failed to identify the presence of disease and relapses. Ceramide-C14-a significant contributor to differentiating EDSS > 3.0-positively correlated with EDSS, while its levels were independent of age and the presence of relapses. This characteristic was unique from those of sNfL and sGFAP, which were affected by age and relapses as well as EDSS.CONCLUSION:
Plasma sphingolipids may be useful NMOSD biomarkers for disability with distinct characteristics compared to sNfL and sGFAP.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esfingolipídeos
/
Biomarcadores
/
Neuromielite Óptica
/
Proteínas de Neurofilamentos
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mult Scler Relat Disord
Ano de publicação:
2024
Tipo de documento:
Article